Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425217 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14173870 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14184351 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3420327 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7305888 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3425220 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14387718 | 0.88 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14184060 | 0.88 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL15961866 | 0.88 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14184101 | 0.87 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051980-B1 | Dopamine transporter imaging agents | HARVARD COLLEGE (US) | 2010-12-15 | — | — | EP | claimed |
| EP-1518562-A2 | Dopamine transporter imaging agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-03-30 | — | — | EP | claimed |
| US-20020131931-A1 | Boat tropanes | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2002-09-19 | — | — | US | claimed |
| EP-1238978-A2 | Intermediates for the synthesis of radiolabelled tropanes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-09-11 | — | — | EP | claimed |
| EP-1051980-A2 | Dopamine transporter imaging agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-11-15 | — | — | EP | claimed |
| EP-1051980-B1 | Dopamine transporter imaging agents | HARVARD COLLEGE (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20090048284-A1 | THERAPEUTIC COMPOUNDS | MELTZER PETER C | 2009-02-19 | — | — | US | disclosed |
| US-7439264-B2 | Therapeutic compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-10-21 | — | — | US | disclosed |
| US-20070009432-A1 | Boat tropanes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-01-11 | — | — | US | disclosed |
| US-7105678-B2 | Boat tropanes | ORGANIX, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1518562-A2 | Dopamine transporter imaging agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1518561-A2 | Dopamine transporter imaging agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20030232827-A1 | Therapeutic compounds | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2003-12-18 | — | — | US | disclosed |
| US-6548041-B1 | Diagnosis, therapy of central nervous system disorders | ORGANIX, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020131931-A1 | Boat tropanes | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2002-09-19 | — | — | US | disclosed |
| EP-1238978-A2 | Intermediates for the synthesis of radiolabelled tropanes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1051980-A2 | Dopamine transporter imaging agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232827-A1 | Therapeutic compounds | SLC10A1, SLC6A2, SLC47A1 | SLC6A3 6/4885SLC6A4 11/4885SLC6A2 2/4885 |
| US-20020131931-A1 | Boat tropanes | SLC6A3, SLC18A2, SLC6A4 | SLC6A3 1/4885SLC6A4 3/4885SLC6A2 4/4885 |
| US-20090048284-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, SLC6A2, SLC47A1 | SLC6A3 6/4885SLC6A4 11/4885SLC6A2 2/4885 |
| US-20070009432-A1 | Boat tropanes | SLC6A3, SLC18A2, SLC6A4 | SLC6A3 1/4885SLC6A4 3/4885SLC6A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.